Serina Reports Q3 Results & Recommits To SER-252 Trials
Serina Therapeutics reported Q3 earnings and said an independent panel recommended advancing its Parkinson's disease drug SER-252 to the next dose cohort, with safety data supporting continued development.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed